The Food and Drug Administration(FDA)has approved two mechanism-based treatments for tuberous sclerosis complex(TSC)-everolimus and vigabatrin.However,these tre
BACKGROUND Dentinogenic ghost cell tumor (DGCT) is an uncommon locally invasive odontogenic neoplasm. It is considered to be a solid variant of calcifying odont